Начало・Списък с акции・Alkermes PLC

Alkermes PLC

Затворен

СекторЗдравеопазване

48.98 1.28

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

48.87

Максимум

49.42

Ключови измерители
By Trading Economics
Приходи	67M 501K
Продажби	103M 496M
P/E Средно за сектора	130.342 68.51
EPS	0.52
Марж на печалбата	0.101
Служители	2,050
EBITDA	76M 54M

Препоръки
By TipRanks
Препоръки	Купи
12-месечна прогноза	+18.47% upside

Дивиденти
By Acuity
Следващи печалби	27.10.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-480M 8.3B
Предишно отваряне	47.7
Предишно затваряне	48.98

Настроения в новините

By Acuity

10%

90%

6 / 340 Класиране в Healthcare

Alkermes PLC Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

6.08.2026 г., 19:36 ч. UTC

Alkermes Plc shares are lower today, reflecting unusual volatility and trading significantly below the 20-day moving average. No specific news was identified.

5.08.2026 г., 19:56 ч. UTC

Alkermes Plc shares are lower Wednesday, continuing a decline since Tuesday's close, despite broader market optimism from falling oil prices and potential diplomatic resolutions.

4.08.2026 г., 19:26 ч. UTC

News

Alkermes Plc shares are lower today amid concerns over recent insider sales by executives, despite the company's gross margin of 80.22%.

3.08.2026 г., 20:02 ч. UTC

Alkermes shares are higher today, driven by significant gains in the overall market and major technology stocks, despite earlier session pullbacks.

31.07.2026 г., 19:36 ч. UTC

Alkermes Plc shares are lower today, impacted by declines in the Biotechnology sub-sector. The stock remains below its 20-day moving average.

30.07.2026 г., 19:58 ч. UTC

Alkermes Plc shares are higher during Thursday's session, reflecting a broader recovery in tech shares despite remaining below the 20-day moving average.

29.07.2026 г., 20:03 ч. UTC

News

Macro Event

Shares declining despite price target increases from JP Morgan, Baird.

28.07.2026 г., 20:02 ч. UTC

News

Event

Alkermes Plc shares are lower after reporting second-quarter earnings of 0 cents per share, below the consensus estimate of 29 cents.

24.07.2026 г., 19:46 ч. UTC

Alkermes Plc shares are lower today, pulling back after an early high. No specific news has been identified to explain the decline.

22.07.2026 г., 19:36 ч. UTC

Alkermes Plc shares are lower today, despite an earlier session high, amid rising crude oil prices and concerns over potential supply disruptions.

21.07.2026 г., 18:46 ч. UTC

Alkermes shares are higher today, supported by improved market sentiment and renewed interest in AI stocks. The asset is trading near its one-month range high.

20.07.2026 г., 22:01 ч. UTC

Alkermes Plc shares declined after-market, retracing from earlier peaks. The asset is currently below its 20-day moving average.

Сравнение с други в отрасъла

Ценова промяна

Alkermes PLC Прогноза

Ценова цел

By TipRanks

18.47% нагоре

12-месечна прогноза

Среден 58.25 USD 18.47%

Висок 65 USD

Нисък 38 USD

Според 12 анализатори от Wall Street, предложили 12-месечна ценова цел за Alkermes PLC през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

12 ratings

Купи

Задържане

Продай

Според 12 анализатори, дали борсови рейтинги на Alkermes PLC през последните 3 месеца.

Настроение

By Acuity

6 / 340 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Alkermes PLC

Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS). The Company's products include ARISTADA, VIVITROL, INVEGA SUSTENNA, XEPLION, INVEGA TRINZA, TREVICTA, RISPERDAL CONSTA, AMPYRA, FAMPYRA, BYDUREON, Aripiprazole lauroxil, ALKS 5461, ALKS 3831, ALKS 8700, ALKS 6428, ALKS 4230 and ALKS 7119. The Company's product platforms include injectable extended-release microsphere technology, LinkeRx technology, NanoCrystal technology and oral controlled release (OCR) technology. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia.